Roche Holding


Competition intensifies in already crowded multiple sclerosis space

05/09/19 -"Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. While this would dent the sales of Aubagio, Novartis’ ..."

Pages
58
Language
English
Published on
05/09/19
You may also be interested by these reports :
12/09/19
Merck held an investors’ day. Summarising findings and discussions, Merck confirmed our positive view. Management delivered what it had announced ...

05/09/19
Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. ...

16/08/19
Our last Novozymes (Add, Denmark) Teaser was aptly titled, ‘Crude-driven Novozymes’. That proved right, again and sadly on the way down. This, in ...

23/07/19
Sanofi (Add, France) has been a story of disorientation, as we have repeatedly asserted. Some solid assets rekindle phases of hope every now and then ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO